SCHEMBL15569149

SCHEMBL15569149

Cc1ccc(C(Nc2cncc(Br)c2)C(N)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.47
CSF1R P07333 1/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 1/20 0.46
EGFR P00533 1/20 0.41
NPC1 O15118 2/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.39
KCNJ11 Q14654 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
CNR1 P21554 1/20 0.37
ROCK2 O75116 1/20 0.37
ALOX5 P09917 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569879 0.87 EGFR (0.41) SYKCSF1REGFRKCNJ11KMT2A
SCHEMBL15569787 0.86 SYK (0.51) SYKCSF1RRAB9AHTTEGFR
SCHEMBL15798219 0.86 SYK (0.51) SYKCSF1RRAB9AHTTEGFR
SCHEMBL15569968 0.86 CSF1R (0.51) SYKCSF1RRAB9AHTTNPC1
SCHEMBL15569576 0.80 CYP2A6 (0.40) SYKCSF1RHTTGAAPOLB
SCHEMBL15570209 0.80 CSF1R (0.42) SYKCSF1RRAB9AHTTNPC1
SCHEMBL15569806 0.79 L3MBTL1 (0.47) SYKCSF1RRAB9ANPC1POLB
SCHEMBL15569778 0.79 SYK (0.48) SYKCSF1RKCNJ11MEN1KMT2A
SCHEMBL15569748 0.76 SYK (0.41) SYKRAB9AHTTNPC1SMN1; SMN2
SCHEMBL16766182 0.75 FPR2 (0.47) SYKCSF1RRAB9AHTTEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US disclosed
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US disclosed
EP-2888232-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2015-07-01 EP disclosed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014029726-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER TP53, RB1, HCCS SYK 3149/4885CSF1R 862/4885RAB9A 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.